© 2023 MJH Life Sciences and Drug Topics. All rights reserved.
© 2023 MJH Life Sciences™ and Drug Topics. All rights reserved.
November 14, 2022
As the main course of treatment for cancer-related pain, the use of opioids comes with a number of issues for both patients and prescribers.
Timing of treatment initiation is crucial for patients with cancer.
November 11, 2022
Collecting data on social determinants of health carries a number of issues and needs to be improved to create learning health systems.
While the use of chemotherapy at end of life is decreasing, the use of immunotherapy is increasing.
November 08, 2022
Follow-ups from pharmacists show a significant increase in outpatient antiemetic drugs prescribed and quality of life in patients experiencing chemotherapy-induced nausea and vomiting.
November 07, 2022
Tackling Medicare Part D drug costs takes more than just capping costs.
Childhood cancer survivors are high risk of pain and in need of pain relief. Did 2016 guidelines for opioid prescribing change use in this group?
October 28, 2022
The study looked at cancer patients as a group, but senior author notes that ‘that treatments for blood cancers are very costly and many of them require treatment for long periods of time.’
October 27, 2022
Because it is ‘off the shelf,’ Tecvayli may have advantages over the CAR-T therapies, which are custom made for each patient and involve harvesting the patient's T cells.
October 19, 2022
Escalating costs are hitting patients hard. CMS price negotiation and the $2,000 cap on Part D out-of-pocket expenses should benefit many patients with Medicare coverage.